FDA Inspection 1313526 — Summit Rx Inc

Summit Rx Inc — FEI 3024347609

The FDA completed an inspection of Summit Rx Inc on Apr 23, 2026 in Bayonne, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Food/Cosmetics.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Apr 23, 2026
Fiscal Year
2026
Product Type
Food/Cosmetics
Project Area
Food Composition, Standards, Labeling and Econ
Location
Bayonne, NJ (United States)

Citations

IDCFRDescription
1570221 CFR 111.320(b)Examination, testing; scientifically valid

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.